Anadys Looks To Head Of Class In HCV Polymerase Inhibitors With Setrobuvir
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech believes strong safety profile and resistance to viral breakthrough could move setrobuvir past Pharmasset's PSI-7977 and other polymerase inhibitors in development in hepatitis C.
You may also be interested in...
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.
Roche Agrees To Acquire HCV Biotech Anadys For $230 Million
Roche will combine Anadys' experimental non-nucleoside polymerase inhibitor with its own protease inhibitor and nucleoside in the effort to establish an all-oral combination therapy for hepatitis C.
Pharmasset: A Breakout Year But Big Catalysts Lie Ahead
Although only half over, 2011 already has been pivotal for hepatitis C drug development, with the launch of two paradigm-shifting protease inhibitors, Johnson & Johnson/Vertex Pharmaceuticals Inc.'s Incivek (telaprevir) and Merck & Co.'s Victrelis (boceprevir). Both hit the market in May, even as attention is now shifting to the next big advance in HCV. Based on its work on next-gen HCV treatment, Pharmasset, Inc. has captivated the investment community.